Keywords: corgentech, eczema, drug, advances, ph, i/ii, biopharmaceutical

Corgentech's eczema drug advances to Ph I/II

Article | 16 May 2005

Print This

US biopharmaceutical firm Corgentech says that it hopes to initiate two Phase I/II clinical trials of NF-kB Decoy for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in